Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Drug Profile

Research programme: antibacterial ribosomal protein inhibitors - Melinta Therapeutics

Alternative Names: RX 01413; RX 01423; RX 01445; RX-01; RX-01(a); RX-01(b); RX-01_413; RX-01_423; RX-01_445; RX-02; RX-03; RX-04; RX-04A; RX-04B; RX-04C; RX-04D; RX-05; RX-230; RX-5312; RX-6425; RX-6567; RX-P2177; RX-P770; RX-P873

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rib-X Pharmaceuticals
  • Developer Melinta Therapeutics
  • Class Macrolides; Oxadiazoles; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
  • 09 Aug 2017 Melinta Therapeutics plans a clinical trial for Bacterial infections (PO) in 2018
  • 05 Jun 2017 Pharmacodynamics data from preclinical studies in Bacterial infections released by Melinta Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top